Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc/r with ADT and Radiotherapy in High-Risk Prostate Cancer
NCT03066154Phase 1Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ModraDoc006 in prostate cancer (PCa), sponsored by Netherlands Cancer Institute. Primary endpoint: Maximal Tolerated Dose at 12 months. Started Sep 2016; status: terminated.
02
Drugs
ModraDoc006
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03066154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066154.